对于晚期卵巢癌患者的细胞减少手术通常需要切除膈肌的全部厚度[1]。在大多数情况下，膈肌可以直接缝合；但是，如果缺陷宽阔而简单的缝合很困难，则通常会使用合成网格进行修复[2]。然而，存在并发肠道切除时，使用这种类型的网格是矛盾的，因为存在细菌污染的风险[3]。自体组织比人工材料具有更高的抗感染能力[4]；因此，在细胞减少治疗晚期卵巢癌时，我们采用自体股膜修复膈肌。一位晚期卵巢癌患者接受了右侧膈肌完整切除，并伴随直肠乙状结肠的切除，取得了完全的切除效果。右侧膈肌的缺陷大小为12×8 cm，直接闭合是不可能的。取下一段大小为10×5 cm的右股膜，用2-0 proline连续缝合线缝合到膈肌缺陷处。股膜的获取只需要20分钟，出血很少。术中和术后没有发生并发症，化疗也没有延误。股膜修复膈肌是一种安全简单的方法，我们特别提出这种修复技术适用于接受肠道切除的晚期卵巢癌患者。此视频使用已获得患者知情同意。©2023。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

Cytoreductive surgery for patients with advanced ovarian cancer often requires full-thickness resection of the diaphragm [1]. In most cases, the diaphragm can be closed directly; however, when the defect is wide and simple closure is difficult, reconstruction using a synthetic mesh is usually performed [2]. However, the use of this type of mesh is contraindicated in the presence of concomitant intestinal resections because of the risk of bacterial contamination [3]. Autologous tissue shows a higher resistance to infection than artificial materials [4]; thus, we introduce diaphragm reconstruction using autologous fascia lata during cytoreduction for advanced ovarian cancer. A patient with advanced ovarian cancer underwent right diaphragmatic full-thickness resection with concomitant resection of the rectosigmoid colon, and complete resection was achieved. The defect of the right diaphragm measured 12×8 cm, and direct closure was impossible. A section of the right fascia lata measuring 10×5 cm was harvested and sutured to the diaphragmatic defect with a 2-0 proline continuous suture. The harvesting of the fascia lata required only 20 minutes, with little blood loss. No intraoperative or postoperative complications were experienced, and adjuvant chemotherapy was initiated without any delay. Diaphragm reconstruction with the fascia lata is a safe and simple method, and we propose this reconstruction technique especially for patients with advanced ovarian cancer who undergo concomitant intestinal resections. The informed consent for use of this video was taken from the patient.© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.